NCT04521686 2026-04-22Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 MutationsEli Lilly and CompanyPhase 1 Active not recruiting200 enrolled
NCT06176989 2026-04-08Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base TumorsNational Institutes of Health Clinical Center (CC)Phase 2 Recruiting40 enrolled